Found: 6
Select item for more details and to access through your institution.
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2578, doi. 10.1111/dom.15572
- By:
- Publication type:
- Article
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 2, p. 274, doi. 10.1002/ejhf.3101
- By:
- Publication type:
- Article
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER, RE-COVER™ II, and RE-MEDY™.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2017, v. 43, n. 4, p. 484, doi. 10.1007/s11239-017-1479-z
- By:
- Publication type:
- Article
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER<sup>®</sup>, RE-COVER™ II, and RE-MEDY™.
- Published in:
- Vascular Medicine, 2016, v. 21, n. 6, p. 506, doi. 10.1177/1358863X16668588
- By:
- Publication type:
- Article
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 7, p. 2826, doi. 10.1007/s12325-024-02879-w
- By:
- Publication type:
- Article
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-319-OR
- By:
- Publication type:
- Article